Clinical Trials Logo

Filter by:
NCT ID: NCT00446121 Withdrawn - Clinical trials for Chronic Obstructive Pulmonary Disease

Inhaled Mannitol and Ciliary Beat Frequency in COPD Patients

Start date: January 2010
Phase:
Study type: Observational

The main purpose of the study is to evaluate the effect of mannitol on the cilia's beat frequency (ciliary beat frequency) in COPD patients.

NCT ID: NCT00420797 Withdrawn - Faecal Incontinence Clinical Trials

A Study to Evaluate Topical Phenylephrine Gel in the Management of Faecal Incontinence

Start date: February 2007
Phase: Phase 3
Study type: Interventional

The aim of the study is to test the hypothesis that topical application of phenylephrine improves faecal continence and quality of life in subjects with passive faecal incontinence after ileo-anal pouch construction.

NCT ID: NCT00417443 Withdrawn - Clinical trials for Postoperative Hyperalgesia

Epidural Clonidine for Postoperative Hyperalgesia

Start date: December 2007
Phase: Phase 3
Study type: Interventional

We propose performing a study in which we compare the effects of bupivacaine and fentanyl with a different drug combination − bupivacaine and clonidine. The principal research questions of the study are: 1. To compare the effect of clonidine (with bupivacaine), injected into the epidural space on the extent of hyperalgesia (abnormal pain/sensitivity in the uninjured skin surrounding the operation site) in patients undergoing operations for bowel disease, with that of fentanyl (with bupivacaine). 2. To compare the effect of clonidine (with bupivacaine), injected into the epidural space on the incidence of chronic pain 6 months after surgery for bowel disease, with that of fentanyl (with bupivacaine).

NCT ID: NCT00398892 Withdrawn - Clinical trials for Diabetes Mellitus, Type 2

The Effects of Lipoic Acid on Glycaemic Control in Type 2 Diabetes

Start date: December 2009
Phase: Phase 2
Study type: Interventional

Hypothesis: that lipoic acid supplements taken orally will improve control of blood sugar levels in people with type 2 diabetes. This study will recruit 18 people with type 2 diabetes, whose diabetes is currently managed on oral agents. Each subject will then either take placebo for 12 weeks followed by lipoic acid for 12 weeks, or lipoic acid followed by placebo. A blood test for overall diabetes control will be taken at the start and end of each 12 week period, and the change in control will be compared for lipoic acid vs placebo.

NCT ID: NCT00382837 Withdrawn - Clinical trials for Systemic Lupus Erythematosus

Study of Epratuzumab in Systemic Lupus Erythematosus

Start date: January 2007
Phase: Phase 3
Study type: Interventional

Epratuzumab is an investigational antibody designed to help treat SLE. The purpose is to evaluate safety and long term efficacy in concert with standard SLE treatments

NCT ID: NCT00349518 Withdrawn - Clinical trials for Acute Lymphoblastic Leukemia

Study of Dasatinib in Imatinib Resistant or Intolerant Subjects With Chronic or Advanced Phase CML or Philadelphia Chromosome Positive ALL

Start date: December 2006
Phase: Phase 2/Phase 3
Study type: Interventional

The purpose of this study is to further assess the safety of dasatinib in imatinib intolerant or resistant patients with chronic phase chronic myeloid leukemia, advanced phase chronic myeloid leukemia or Philadelphia chromosome positive acute lymphoblastic leukemia. The efficacy of the drug in this kind of patients will also further be documented.

NCT ID: NCT00342940 Withdrawn - Influenza Clinical Trials

Safety and Immunogenicity of a Commercially Available Influenza Vaccine (Formulation 2006/2007) When Administered to Subjects 18 Years of Age or Older

Start date: October 2006
Phase: Phase 2
Study type: Interventional

The present study aims to evaluate safety and immunogenicity of one dose of a commercially available Surface Antigen, Inactivated Influenza Vaccine, Formulation 2006-2007, in non-elderly adult and elderly subjects.

NCT ID: NCT00335621 Withdrawn - Clinical trials for Chronic Obstructive Pulmonary Disease

Replacement of Nebulised Ipratropium With Inhaled Tiotropium in Stable Chronic Obstructive Pulmonary Disease (COPD)

Start date: June 2006
Phase: Phase 4
Study type: Interventional

Some patients with chronic obstructive pulmonary disease (COPD) take nebulised treatments to ease the symptom of breathlessness, including the drug ipratropium. Nebulised bronchodilator drugs are taken up to 4 times through the day, and this can take up to 15 minutes each time. Although the treatment isbe effective, patients report that the time taken to set-up and use the nebuliser can be a disincentive to regular use. By contrast, an inhaler device is easy to use following appropriate instruction, and takes only a few seconds to administer. Inhaled tiotropium is a once daily treatment taken by inhaler which has been shown to be effective in COPD. We wish to assess whether inhaled Tiotropium as effective as nebulised ipratropium in patients with stable chronic obstructive pulmonary disease.

NCT ID: NCT00298402 Withdrawn - Clinical trials for Chronic Obstructive Pulmonary Disease

Macrophages in Smokers' Lung

Start date: October 2005
Phase: N/A
Study type: Observational

Cigarette smoking causes an increase in inflammation in the lungs. In about 20% of smokers this inflammation leads to damage in lungs including making holes in the lung tissue. This damage can not be repaired and these people find it very difficult to breathe. One of the problems with this disease called chronic obstructive pulmonary disease, or COPD for short, is that by the time patients visit their doctor with symptoms, the damage has already been done. At the moment, there is no way to predict which smokers will go on to develop COPD. The aim of this research is to look at smokers who breathe normally and use an imaging technique called a CT scan, to look at their lungs in more detail. Some of these people will have spots on their scan which may be caused by inflammation. We want to look at the cells at these spots to see if they make more proteins and enzymes that cause lung damage when compared to people that do not have these spots. We would then be able to predict which smokers are likely to develop COPD and treat them early before they have damaged their lungs.

NCT ID: NCT00291408 Withdrawn - Clinical trials for Chronic Obstructive Pulmonary Disease (COPD)

Effect of Symbicort on HAT and HDAC in Sputum Macrophages of COPD

Start date: April 2006
Phase: Phase 4
Study type: Interventional

The purpose of the study is to compare histone acetyltransferase (HAT) and histone deacetylase (HDAC) expressions and activities in induced sputum macrophages obtained from patients with moderate to severe COPD and age-matched normal non-smokers